Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.
Panhaleux M, Espitia O, Terrier B, Manson G, Maria A, Humbert S, Godbert B, Perrin J, Achille A, Arrondeau J, Kostine M, Fallet V, Pugnet G, Chaigne B, Champiat S, Laparra A, Danlos FX, Launay D, Penel N, Lambotte O, Michot JM, Forestier A.
Panhaleux M, et al. Among authors: forestier a.
Eur J Cancer. 2022 Jan;160:134-139. doi: 10.1016/j.ejca.2021.10.018. Epub 2021 Nov 19.
Eur J Cancer. 2022.
PMID: 34810048
Clinical Trial.